The drug giant's winning ways look set to continue for a while.It's hard not to admire what Eli Lilly (LLY 1.53%) has accomplished over the past five years. The drugmaker has been riding a wave of strong financial results and excellent regulatory progress to become the largest healthcare company by market capitalization. It's inching closer to a $1 trillion valuation -- and at the rate it has been going, don't be surprised if it hits that milestone within a year.However, despite the terrific gains Eli Lilly ...

Key TakeawaysEli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and weight-loss drugs.The company's Alzheimer's drug, Kisunla, was approved by the U.S. Food and Drug Administration last month.Eli Lilly has committed more than $20 billion to manufacturing investments in the U.S. and Europe since 2020. Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingre ...

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry is at its peak, with spaces like weight loss/obesity, inflammation and Alzheimer’s disease attracting investor interest in 2024.Novel diabetes and obesity drugs of Eli Lilly (LLY) and Novo Nordisk have taken the pharma sector by storm with both Eli Lilly’s tirzepatide drugs (Mounjaro and Zepbound) and No ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. The pharmaceutical giant is spending $1 billion to expand an existing site in Limerick, Ireland, to increase the production of certain active ingredients in drugs, including those used ...

There's a little appreciated reason to own Eli Lilly stock, and it has nothing to do with its medicines.Eli Lilly (LLY -0.77%) might just be the hottest pharmaceutical company on the planet right now. The company is the developer of a number of blockbuster drugs including Verzenio, Trulicity, and Taltz.Of course, I'd be remiss to not include the company's latest hits in weight loss. Lilly's diabetes and obesity care medications, Mounjaro and Zepbound, are currently fueling a new wave of growth for the pharm ...

Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.Stock splits can get the market excited, even though nothing changes for the business fundamentally, including its future prospects. So what's the reason behind a rally following a stock split? Once a company's share price goes above a certain psychological threshold, the average investor begins to perceive the stock as "expensive" and worries about being unable to buy enough (or even whole) shares of that c ...

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsit ...

Eli Lilly has been a big-time winner for investors over the last several decades, and there are many reasons to believe the company is at the forefront of many new growth stories.A couple of months ago, I stumbled across a podcast featuring Palantir co-founder Joe Lonsdale and Home Depot co-founder Ken Langone. During their talk, Lonsdale asked Langone several questions related to his investment philosophy. Initially, I thought these questions were a little bizarre. After all, given Home Depot's success ove ...

This drugmaker should have a basketful of growth drivers over the next decade.Eli Lilly (LLY -1.10%) stands atop the biopharmaceutical world. It's the biggest drugmaker by far based on market cap. Lilly's share price has skyrocketed nearly 700% over the last five years and is up close to 55% in 2024.Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for treating type 2 diabetes and obesity, respectively. But Mounjaro and Zepbound aren' ...

Merck & Co., Inc. NYSE: MRK is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO, with a market capitalization of $294 billion.The company’s forward price-to-earnings (P/E) ratio sits at 13x. Compared to a peer group of the world's 10 largest pharma companies, this is well below the average of 20x. According to FactSet Earnings Insight, the healthcare sector has experienced the fourth-largest earnings growth in the p ...